INS and type 2 diabetes mellitus: In patients with type 2 diabetes, clinical studies indicate that adding exenatide twice daily to basal insulin results in robust reductions in HbA1c, modest weight reduction, no significant increase in hypoglycaemia and (in observational studies) a possible reduction in insulin dose.